Table 2.
Subgroup analyses for the outcome of relapse
| Subgroups | No. of studies | HR (95% CI) | I2 (P value) |
|---|---|---|---|
| Population | |||
| Children | 5 | 3.30 (1.48–7.36) | 73.1% (0.01) |
| Adult | 4 | 2.90 (1.85–4.57) | 8.5% (0.35) |
| Design | |||
| Prospective | 7 | 4.21 (1.93–9.16) | 62.2% (0.01) |
| Retrospective | 5 | 2.73 (1.96–3.79) | 7.1% (0.37) |
| Region | |||
| Europe | 7 | 3.21 (1.80–5.71) | 61.3% (0.02) |
| USA | 4 | 3.27 (2.00–5.36) | 24.6% (0.26) |
| Asia | 1 | 7.34 (0.54–99.59) | – |
| Detection method | |||
| PCR | 7 | 3.82 (1.94–7.53) | 62.0% (0.02) |
| FC | 4 | 3.10 (1.92–5.02) | 17.0% (0.31) |
| Adjustment | |||
| Adjusted | 7 | 3.24 (2.10–5.00) | 32.8% (0.18) |
| Crude | 5 | 3.43 (1.59–7.38) | 64.6% (0.02) |
| Competing risk framework | |||
| Yes | 10 | 2.96 (2.22–3.96) | 52.9%(0.02) |
| No | 2 | 2.40(1.45–3.98) | 0.0 (0.39) |